



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/618,148
Filing Date: July 10, 2003
Confirmation No.: 4138
Title: USE OF RIBOFURANOSE DERIVATIVES AGAINST
INFLAMMATORY BOWEL DISEASE

Mail Stop Issue Fee
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

CHANGE OF FEE ADDRESS

CHANGE OF ATTORNEY DOCKET NUMBER

Sir:

Please refer to attorney docket number **6319-1950** in all future communications relating to this patent.

Please address all future correspondence in connection with this patent to:


Customer No. 29858

Respectfully submitted,

Dated: June 28, 2005

James P. Demers
James P. Demers
Reg. No. 34,320

BROWN RAYSMAN MILLSTEIN FELDER & STEINER LLP
900 Third Avenue
New York, New York 10022
(212) 895-2000



PTO/SB/96 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Valeant Pharmaceuticals InternationalApplication No./Patent No.: 10/618,148 Filed/Issue Date: July 10, 2003Entitled: USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASEValeant Pharmaceuticals International, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Victor Brantl To: ICN Pharmaceuticals Switzerland Ltd.
The document was recorded in the United States Patent and Trademark Office at
Reel 014284, Frame 0462, or for which a copy thereof is attached.
2. From: ICN Pharmaceuticals Switzerland Ltd. To: Valeant Pharmaceuticals International
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: Valeant Pharmaceuticals/International To: Ribapharm Pharmaceuticals
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 17, 2005

Date

(714) 545-0100 x3124

Telephone number

Eileen C. Pruette

Typed or printed name

Signature

Executive Vice President

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BRMFS1 574811v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/80 (12-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby appoint:

☒ Practitioners associated with the Customer Number:

29858

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

| Name | Registration Number |
|------|---------------------|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).


Assignee Name and Address:

Ribapharm Inc.
3300 Hyland Avenue
Costa Mesa, CA 92626

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

| | | | |
|-----------|---|-----------|----------------|
| Name | Mel Deutsch | | |
| Signature |  | Date | 3-17-04 |
| Title | VP, General Counsel & Secretary | Telephone | (714) 545-0100 |

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT OF PATENT RIGHTS FOR THE UNITED STATES

FOR VALUE RECEIVED, **ICN PHARMACEUTICALS SWITZERLAND LTD.**, having a place of business at Ruhrbergstrasse 21, CH-4127 Birsfelden, Switzerland, hereby sells, assigns, transfers and conveys unto

VALEANT PHARMACEUTICALS INTERNATIONAL

having a place of business at 3300 Hyland Avenue, Costa Mesa, California 92626,

its successors, assigns and legal representatives (hereinafter called the "Assignee"), the entire right, title and interest, for the United States, in and to certain inventions relating to for which an application for United States Letters Patent entitled:

**USE OF RIBOFURANOSE DERIVATIVES AGAINST
INFLAMMATORY BOWEL DISEASES**

attorney docket number 86689.0006

- ✓ filed with the U.S. Patent and Trademark Office on July 10, 2003, and assigned Serial Number 10/618,148;

and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues and extensions thereof; and we hereby authorize and request the Commissioner for Patents and Trademarks of the United States to issue all Letters Patent upon said inventions to the Assignee or to such nominees as it may designate.

AND we authorize and empower the said Assignee or nominees to invoke and claim for any application for patent or other form of protection for said inventions filed by it or them, the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from us.

AND we hereby consent that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in the United States for any purpose and more particularly in proof of the right of said Assignee or nominees to claim the aforesaid benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it.

AND we hereby covenant that we have the full right to convey the entire

right, title and interest herein assigned, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND we hereby covenant and agree that we will communicate to said Assignee or nominees all facts known to us pertaining to said inventions, and testify in all legal proceedings, sign all lawful papers, execute all continuing and reissue applications, make all rightful oaths and declarations and in general perform all lawful acts necessary or proper to aid said Assignee or nominees in obtaining, maintaining and enforcing all lawful patent protection for said inventions in the United States.

IN TESTIMONY WHEREOF, I hereunto set my hand this 19th day of November, 2004.

By: (Signature) [Signature]

(Name) V. BRANTIC

(Title) EVP, R&D

ICN PHARMACEUTICALS
SWITZERLAND Ltd

By: (Signature) [Signature]

(Name) J. REHAK

(Title) Director, Project Mughit. R&D

ICN PHARMACEUTICALS
SWITZERLAND Ltd

ASSIGNMENT OF PATENT RIGHTS FOR THE UNITED STATES

FOR VALUE RECEIVED, and pursuant to the Contribution Agreement entered into by the parties on August 20, 2002, VALEANT PHARMACEUTICALS INTERNATIONAL, having a place of business at 3300 Hyland Avenue, Costa Mesa, California 92626, hereby sells, assigns, transfers and conveys unto

RIBAPHARM PHARMACEUTICALS

having a place of business at 3300 Hyland Avenue, Costa Mesa, California 92626, its successors, assigns and legal representatives (hereinafter called the "Assignee"), the entire right, title and interest, for the United States, in and to certain inventions relating to for which an application for United States Letters Patent entitled:

**USE OF RIBOFURANOSE DERIVATIVES AGAINST
INFLAMMATORY BOWEL DISEASES**

attorney docket number 86689.0006

- ✓ filed with the U.S. Patent and Trademark Office on July 10, 2003, and assigned Serial Number 10/618,148;

and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues and extensions thereof, and we hereby authorize and request the Commissioner for Patents and Trademarks of the United States to issue all Letters Patent upon said inventions to the Assignee or to such nominees as it may designate.

AND we authorize and empower the said Assignee or nominees to invoke and claim for any application for patent or other form of protection for said inventions filed by it or them, the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from us.

AND we hereby consent that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in the United States for any purpose and more particularly in proof of the right of said Assignee or nominees to claim the aforesaid benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it.

AND we hereby covenant that we have the full right to convey the entire right, title and interest herein assigned, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND we hereby covenant and agree that we will communicate to said Assignee or nominees all facts known to us pertaining to said inventions, and testify in all legal proceedings, sign all lawful papers, execute all continuing and reissue applications, make all rightful oaths and declarations and in general perform all lawful acts necessary or proper to aid said Assignee or nominees in obtaining, maintaining and enforcing all lawful patent protection for said inventions in the United States.

IN TESTIMONY WHEREOF, I hereunto set my hand this 4th day of January, 2005.

By: (Signature) Eileen C. Pruette
(Name) Eileen C. Pruette
(Title) Exec. V.P., General Counsel

VALEANT PHARMACEUTICALS
INTERNATIONAL